Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559173 | 1.00 | IKBKB (1.00) | IKBKBCHUK | |
| SCHEMBL4510218 | 1.00 | IKBKB (1.00) | IKBKBCHUK | |
| Hydrochloric Acid SCHEMBL4500337 | 0.99 | IKBKB (0.98) | IKBKBCHUK | |
| Hydrochloric Acid SCHEMBL4514515 | 0.99 | IKBKB (0.98) | IKBKBCHUK | |
| Hydrochloric Acid SCHEMBL4509040 | 0.99 | IKBKB (0.98) | IKBKBCHUK | |
| SCHEMBL4614268 | 0.90 | IKBKB (0.82) | IKBKBCHUK | |
| SCHEMBL4613934 | 0.90 | IKBKB (0.81) | IKBKB | |
| Hydrochloric Acid SCHEMBL30341853 | 0.90 | IKBKB (0.81) | IKBKBCHUK | |
| SCHEMBL4612399 | 0.89 | IKBKB (0.80) | IKBKBCHUK | |
| SCHEMBL14028520 | 0.88 | IKBKB (0.78) | IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054424-A1 | Optically active pyridine derivative and a medicament containing the same | MURATA TOSHIKI | 2009-02-26 | — | — | US | claimed |
| US-7375103-B2 | Optically active pyridine derivative and a medicament containing the same | BAYER HEALTHCARE AG (DE) | 2008-05-20 | — | — | US | claimed |
| EP-1487842-B1 | AN OPTICALLY ACITVE PYRIDINE DERIVATIVE AND A MEDICAMENT CONTAINING THE SAME | BAYER HEALTHCARE AG (DE) | 2007-03-14 | — | — | EP | claimed |
| US-20050215547-A1 | Optically active pyridine derivative and a medicament containing the same | BAYER HEALTHCARE AG (DE) | 2005-09-29 | — | — | US | claimed |
| EP-3288558-B1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma AG (DE) | 2022-05-11 | — | — | EP | disclosed |
| EP-3423446-B1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | Bayer Pharma AG (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-10758522-B2 | Small molecule analogs of the nemo binding peptide | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-09-01 | — | — | US | disclosed |
| US-10435396-B2 | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs | BAYER PHARMA AKTIEGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| US-10226469-B2 | Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines for treating lymphomas | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-12 | — | — | US | disclosed |
| US-20190071432-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-07 | — | — | US | disclosed |
| EP-3423446-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-20180289685-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-11 | — | — | US | disclosed |
| US-7375103-B2 | Optically active pyridine derivative and a medicament containing the same | BAYER HEALTHCARE AG (DE) | 2008-05-20 | — | — | US | disclosed |
| EP-1487842-B1 | AN OPTICALLY ACITVE PYRIDINE DERIVATIVE AND A MEDICAMENT CONTAINING THE SAME | BAYER HEALTHCARE AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| EP-1487842-B1 | AN OPTICALLY ACITVE PYRIDINE DERIVATIVE AND A MEDICAMENT CONTAINING THE SAME | BAYER HEALTHCARE AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| EP-1487842-B1 | AN OPTICALLY ACITVE PYRIDINE DERIVATIVE AND A MEDICAMENT CONTAINING THE SAME | BAYER HEALTHCARE AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| US-20050215547-A1 | Optically active pyridine derivative and a medicament containing the same | BAYER HEALTHCARE AG (DE) | 2005-09-29 | — | — | US | disclosed |
| EP-1487842-A1 | AN OPTICALLY ACITVE PYRIDINE DERIVATIVE AND A MEDICAMENT CONTAINING THE SAME | Bayer HealthCare AG (DE) | 2004-12-22 | — | — | EP | disclosed |
| JP-2003277383-A | OPTICALLY ACTIVE PYRIDINE DERIVATIVE AND MEDICINE CONTAINING THE SAME | BAYER AG | 2003-10-02 | — | — | JP | disclosed |
| WO-2003076447-A1 | AN OPTICALLY ACITVE PYRIDINE DERIVATIVE AND A MEDICAMENT CONTAINING THE SAME | BAYER HEALTHCARE AG (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435396-B2 | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs | CYP11B2, CYP19A1, CYP11B1 | IKBKB 347/4885CHUK 315/4885 |
| US-10758522-B2 | Small molecule analogs of the nemo binding peptide | IKBKG, NFKBIA, NFKB1 | IKBKB 5/4885CHUK 15/4885 |
| US-20180289685-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | IRAK4, IRAK1, IRAK2 | IKBKB 7/4885CHUK 10/4885 |
| US-20090054424-A1 | Optically active pyridine derivative and a medicament containing the same | IL1B, NFKBIA, IL17A | IKBKB 28/4885CHUK 17/4885 |
| US-20050215547-A1 | Optically active pyridine derivative and a medicament containing the same | IL1B, NFKBIA, IL1A | IKBKB 25/4885CHUK 15/4885 |
| US-10226469-B2 | Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines for treating lymphomas | MALT1, BCL6B, BCL9L | IKBKB 256/4885CHUK 84/4885 |
| US-20190071432-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | CYP11B2, CYP19A1, CYP11B1 | IKBKB 378/4885CHUK 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.